The present disclosure relates to methods and compositions for the treatment of cancer using an ACAT1 inhibitor. The cancer may be any of melanoma, lymphoma, esophageal cancer, liver cancer, head and neck cancer, bladder cancer, endometrial cancer, kidney cancer and thyroid cancer. In some embodiments, the cancer itself it not responsive directly to the ACAT1 inhibitor but is rather treated through the immune system activated by the ACAT1 inhibitor. Combination therapies are also provided, for instance in combination with an alkylating antineoplastic agent.

The present disclosure relates to methods and compositions for the treatment of cancer using an ACAT1 inhibitor. The cancer may be any of melanoma, lymphoma, esophageal cancer, liver cancer, head and neck cancer, bladder cancer, endometrial cancer, kidney cancer and thyroid cancer. In some embodiments, the cancer itself it not responsive directly to the ACAT1 inhibitor but is rather treated through the immune system activated by the ACAT1 inhibitor. Combination therapies are also provided, for instance in combination with an alkylating antineoplastic agent.

The present disclosure provides, inter alia, methods for treating diseases, e.g., a cancer, in a subject by targeting oncogenic lipids in cells, including increasing lipid-based reactive oxygen species (ROS) by inhibiting coenzyme Q.sub.10 (CoQ.sub.10) production. Methods for treating a subject with a cancer that is sensitive to an oncolipid-targeting therapy, e.g., ADCK3 inhibition, are also provided. Further provided are methods for modulating coenzyme Q.sub.10 (CoQ.sub.10) level in a subject, including determining CoQ.sub.10 levels by LC-MS.

The present disclosure provides, inter alia, methods for treating diseases, e.g., a cancer, in a subject by targeting oncogenic lipids in cells, including increasing lipid-based reactive oxygen species (ROS) by inhibiting coenzyme Q.sub.10 (CoQ.sub.10) production. Methods for treating a subject with a cancer that is sensitive to an oncolipid-targeting therapy, e.g., ADCK3 inhibition, are also provided. Further provided are methods for modulating coenzyme Q.sub.10 (CoQ.sub.10) level in a subject, including determining CoQ.sub.10 levels by LC-MS.

Provided here are therapeutically effective pharmaceutical compositions containing one or more TREX2 inhibitors, and more specifically methods of administering TREX2 inhibitors to increase the effectiveness of a chemotherapeutic agent. Also provided here are methods of identifying agents that inhibit the exonuclease activity of TREX2.

Provided here are therapeutically effective pharmaceutical compositions containing one or more TREX2 inhibitors, and more specifically methods of administering TREX2 inhibitors to increase the effectiveness of a chemotherapeutic agent. Also provided here are methods of identifying agents that inhibit the exonuclease activity of TREX2.

The present disclosure relates, in general to methods for treating hematologic cancers comprising administering an anti-CD30 antibody drug conjugate in combination with additional cancer therapeutics such as a checkpoint inhibitor, and a chemotherapeutic regimen.

The present disclosure relates, in general to methods for treating hematologic cancers comprising administering an anti-CD30 antibody drug conjugate in combination with additional cancer therapeutics such as a checkpoint inhibitor, and a chemotherapeutic regimen.

[Problem] To provide novel anti-tumor agents and combination drugs.

[Means to solve] To provide an anti-tumor agent containing, as an active ingredient, a glutathione level reducer or a glutathione S-transferase inhibitor, the anti-tumor agent being adapted to be administered simultaneously with an effective amount of a compound (II); an anti-tumor agent including a compound (II) as an active ingredient, the anti-tumor agent being adapted to be administered simultaneously with an effective amount of a glutathione level reducer or a glutathione S-transferase inhibitor; or an anti-tumor agent containing, as active ingredients, a compound (II) and a glutathione level reducer or a glutathione S-transferase inhibitor, where R.sup.5 is a linear or branched C1-6 alkyl group, R.sup.6 is hydrogen or halogen, R.sup.7 is a linear or branched C1-6 alkyl group optionally substituted with a substituent, the substituent being hydroxy or phenyl, and R.sup.8 is hydrogen or halogen.

[Problem] To provide novel anti-tumor agents and combination drugs.

[Means to solve] To provide an anti-tumor agent containing, as an active ingredient, a glutathione level reducer or a glutathione S-transferase inhibitor, the anti-tumor agent being adapted to be administered simultaneously with an effective amount of a compound (II); an anti-tumor agent including a compound (II) as an active ingredient, the anti-tumor agent being adapted to be administered simultaneously with an effective amount of a glutathione level reducer or a glutathione S-transferase inhibitor; or an anti-tumor agent containing, as active ingredients, a compound (II) and a glutathione level reducer or a glutathione S-transferase inhibitor, where R.sup.5 is a linear or branched C1-6 alkyl group, R.sup.6 is hydrogen or halogen, R.sup.7 is a linear or branched C1-6 alkyl group optionally substituted with a substituent, the substituent being hydroxy or phenyl, and R.sup.8 is hydrogen or halogen.